Pathway Therapeutics

About Pathway Therapeutics

Pathway Therapeutics is a clinical stage, privately held, pharmaceutical company developing differentiated isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. The company's lead product, PWT33597, is a balanced, dual PI3K alpha/mTOR inhibitor and the first compound with this profile to enter the clinic. Dual inhibition of PI3K and mTOR shuts down the PI3K/mTOR pathway more effectively than single target inhibitors. Of the four PI3K isoforms, PI3K alpha is the key isoform involved in the growth of solid tumors. PI3K alpha is commonly mutated and amplified across a broad range of tumor types and it is also the key isoform involved in signaling downstream of receptor tyrosine kinases. PWT33597 also inhibits both mTOR complexes 1 and 2 (mTORC1 and mTORC2) to turn off a feedback loop that upregulates PI3K when only mTORC1 (target of rapalogs) is inhibited. The profile of PWT33597 supports clinical development in tumors with PI3K alpha pathway dysregulation, (such as breast, endometrial, colorectal cancer, etc.) and mTOR driven tumors (such as renal cell carcinoma, breast, endometrial, sarcoma, and neuroendocrine tumors). Pathway Therapeutics is also developing PI3K delta inhibitors for the treatment of hematological malignancies, and inflammatory and respiratory diseases. PI3K delta inhibition has been clinically validated in hematological malignancies and there is significant preclinical target validation in multiple inflammatory and respiratory diseases. Pathway Therapeutics has identified a potent and selective development candidate, PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. PWT143 has shown superior activity vs. CAL-101 (GS-1101, a compound with clinical proof of concept), in multiple immune cell types and primary leukemia cells. Pathway Therapeutics is also developing additional PI3K delta inhibitors with orthogonal chemistry to PWT143.